Skip to main content
Journal of Diabetes Science and Technology logoLink to Journal of Diabetes Science and Technology
. 2026 Jan 14:19322968251391819. Online ahead of print. doi: 10.1177/19322968251391819

Research Code Sharing in Support of Gold Standard Science

David C Klonoff 1,2,, Juan Espinoza 3, Julia K Mader 1,4, Lutz Heinemann 1,5, Claudio Cobelli 1,6, David Kerr 1,7, Boris Kovatchev 1,8, Bijan Najafi 1,9, Priya Prahalad 1,10, Yaguang Zheng 1,11, Mandy M Shao 12, Agatha F Scheideman 12, Ashley Y DuNova 12,13, Michael Kohn 14, Guillermo E Umpierrez 15, Tien Y Wong 16,17,18, Aiman Abdel Malek 19,20, Michael S D Agus 21,22, David T Ahn 23, Rawan AlSaad 24, Mohammed E Al-Sofiani 25,26, David Armstrong 27,28,29,30,31, Mark A Arnold 32, Yong Mong Bee 33, B Wayne Bequette 34, Riccardo Bellazzi 35,36, Eda Cengiz 37, J Geoffrey Chase 38, Haipeng Chen 39, Jake Y Chen 40, Simon L Cichosz 41, Ali Cinar 42, Mark A Clements 43, Kelly L Close 44, Jorge Cuadros 45,46, Ivan Contreras 47, Gora Datta 48,49, Ketan Dhatariya 50, Francis J Doyle III 51, Andjela Drincic 52, Andrea Facchinetti 9, G Alexander Fleming 53, Joshua Foreman 45,54,55, Monica A L Gabbay 56, Ricardo Gutierrez-Osuna 57, Elizabeth Healey 21, Thanh D Hoang 58, Peter G Jacobs 59,60, Bernhard Kulzer 61,62, Jeff La Belle 63,64,65,66, Aaron Y Lee 67, Cecilia S Lee 67, Wei-An Lee 68, Dorian Liepmann 69, David Maahs 14,70,71,72,73,74, Nestoras Mathioudakis 26, Sultan A Meo 75, Ahmed A Metwally 76, Shivani Misra 77, Viswanathan Mohan 78,79, Sun-Joon Moon 80, Helge Raeder 81,82, Connie Rhee 83,84, Eun-Jung Rhee 80, David Scheinker 1, Viral N Shah 85, Bin Sheng 86,87, Michael P Snyder 12, Koji Sode 88, Elias K Spanakis 89, Jannet Svensson 90,91, Nitin Vaswani 92,93, Maryam Vareth 94,95,96, Josep Vehi 97, Amisha Wallia 98, Kayo Waki 99, Tao Wang 12, Eric Williams Jr 100, Risa M Wolf 101, Jenise C Wong 102, Sewagegn Yeshiwas 103, Mihail Zilbermint 26,104,105, Shahid N Shah 106
PMCID: PMC12804059  PMID: 41532590

Abstract

Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.

Keywords: code, data, diabetes, Gold Standard Science, reproducibility, repository

Introduction

In this article, we focus on a practical and important complement to data sharing that is aligned with Gold Standard Science (GSS), FAIR (findable, accessible, interoperable, and reusable), and TRUST (transparency, responsibility, user focus, sustainability, technology): pairing each journal article’s cited data snapshot with a versioned and environment-specific code release, deposited in TRUST-aligned repositories. Through this approach, readers can verify results and build reliably on prior work.

The integrity of medical science relies on a foundation of credibility, reproducibility, and transparency to drive innovation and progress in clinical care. These values, which are broadly understood as TRUST, are long recognized by the scientific and medical communities and are now further articulated in the National Institutes of Health’s (NIH) recently published Plan to Drive Gold-Standard Science. 1 In that plan, NIH outlines nine tenets of scientific rigor, beginning with reproducibility and transparency.

These recommendations build on over three decades of the open science movement, which strives to make every stage of research (from planning and data collection to analysis, publication, and reuse) transparent, accessible, and reusable by default. 2 Early anchors include arXiv (1991) for preprints, 3 the Bermuda Principles (1996-1997) for rapid genomic data release, 4 and the Budapest Open Access Initiative (2002) that defined open access and catalyzed policy adoption. 5 In the last decade, communities have standardized how to share and preserve research outputs: the FAIR principles (2016) for making data and code findable, accessible, interoperable, and reusable 6 ; the TRUST principles (2020) for trustworthy repositories 7 ; and FAIR for Research Software (FAIR4RS, 2022) 8 and software-citation guidance for code. 9 Collectively, they have laid the groundwork for credible, reusable science, making it practical to verify findings and build reliably on prior work.

Principles of Open Access Science

Open science emphasizes transparency, reproducibility, and collaboration to make scientific research results—including publications, data, code, physical samples, and methods—openly accessible to everyone. Three quality frameworks—GSS, FAIR, and TRUST—are examples of open science principles. They are complementary, and each provides guidance for different dimensions of the scientific process (Figure 1). NIH’s GSS sets expectations for how science should be done (eg, rigor, transparency, falsifiability, and bias-mitigating peer review), shaping the behaviors of investigators and institutions. Those behaviors yield the scientific record in three parts: (1) manuscripts (the narrative, claims, and insights), (2) datasets (the evidence), and (3) code and computing environment specifications (the method to regenerate results). The FAIR principles specify the qualities of these objects so others can find, access, interoperate with, and reuse them. The TRUST principles specify that these objects should live in repositories with transparent governance, versioning and durable landing pages, user focus, sustainability, and sound technology to ensure long-term citability and stewardship.

Figure 1.

Figure 1.

Three open science frameworks (GSS, FAIR, and Trust) that are complementary to each other and guide different aspects of the scientific process.

Abbreviations: FAIR, findable, accessible, interoperable, and reusable; TRUST, transparency, responsibility, user focus, sustainability, technology.

The 2023 NIH Data Management and Sharing (DMS) Policy codifies parts of this agenda into funder requirements for data: planning, budgeting, and appropriate sharing aligned with privacy, consent, and legal/ethical limits. 2 The policy requires an approved DMS Plan at the time of application, requires updates in progress reports, and allows budgeting for data management and sharing activities. 2 It directs investigators to maximize appropriate sharing of scientific data, typically via trusted research data repositories that support persistent identifiers, versioning, preservation, and clear access models (including controlled access for human-participant data when needed). 2 While the DMS Policy’s primary focus is data, NIH notes that sharing analysis scripts, software, and code is a best practice that strengthens reproducibility; it encourages such sharing but does not mandate public code release. 3

Companion Repositories for Code

The National Institutes of Health does not specify a uniform format for deposited code or that it be made easily sharable. Building on the DMS Policy’s focus on data, code sharing can be improved with standardized practices focused on sharing and reproducibility. For code, there are two practical and complementary approaches: (1) A permanent archive of code releases for citation (eg, archiving versioned releases with unique DOIs) that creates non-mutable, citable snapshots that match a manuscript’s analyses; and (2) An updatable, executable companion code repository for collaboration and reuse where authors can maintain issues, pull requests, and documentation. In the latter setting, code should be open access, meaning that the source is publicly available under a license that permits use, modification, and redistribution. Without an explicit open-source or permissive license, others generally cannot legally modify or redistribute code. 10 Providing a clear license and archiving versioned releases ensures that readers can both reuse the software and cite the exact version used in the study. 11 An updatable and executable companion repository for code complements, rather than replaces, established research data repositories. The contents of a companion repository are listed in Table 1.

Table 1.

Contents of a Companion Repository for Executable and Updatable Code.

• README File: Plain-English run instructions and repository map; link to the manuscript and to the data repository accession/DOI for the exact data snapshot used.
• Analysis code and workflows: Notebooks and scripts (eg, R, Python, Stata/MP syntax exports) and/or workflow files that regenerate all tables, figures, and results without manual edits.
• Computational environment: A machine-readable spec so others can run the code (eg, Dockerfile, environment.yml, requirements.txt), and any version/seed settings needed for deterministic output.
• Provenance and transformation notes: Stepwise description of data preparation (filters, recodes, exclusions, imputation rules), with a data dictionary, naming conventions, schema and references to any taxonomies/ontologies used.
• Public exemplars (optional): Small, non-sensitive sample, aggregate or clearly labeled synthetic files only to demonstrate scripts; the real study data live in a data repository.
• Citation and licensing: CITATION.cff (or equivalent) with how to cite the software, a clear LICENSE (OSI-approved where possible), and instructions for submitting issues, pull requests, etc.
• Versioning and releases: Tagged releases with notes; archive each release to a DOI-issuing service (eg, Zenodo) for a citable, non-mutable snapshot.
• Do not include participant-level human data, secrets, tokens, or other sensitive information in the code repository. Use controlled-access data repositories as appropriate and reference their accession in the README.

Abbreviation: OSI, Open Source Initiative.

The National Institutes of Health encourages the use of collaborative code platforms with long-term sustainability that support web-based development, sharing, integration, issue tracking, and version control. These platforms are often called code repositories or code forges; examples include GitHub, GitLab, and Bitbucket. 12

Executable Code in a Companion Repository

In this context, “executable code” means analysis code that a third party can run end-to-end in a documented computational environment. Authors should provide scripts, notebooks, and an environment specification (eg, container, environment.yml, requirements.txt, or renv.lock) so others can rerun the pipeline. If code is provided in publicly available executable, structured formats, then peer reviewers and secondary researchers can validate analyses, rerun workflows, and detect discrepancies. 13 Even with access to a complete and/or raw dataset with the code to generate the precise analytic dataset, it is possible for code to be non-executable in an environment other than that of the author because of missing supporting code, errors in code, or intentional sharing of illustrative/teaching code rather than fully runnable scripts. As much as 76% of public notebook code is technically non-executable under strict standards. 14 A 2022 study by Trisovic et al 15 of 9000 code files in an open-source data plus code repository platform for sharing, archiving, and citing research data, showed that 74% failed to complete without error in the initial execution, and 56% still failed following code cleaning. For analyses that involve proprietary tools or sensitive code, authors may provide a temporary private link or an access-controlled repository for reviewers to examine the work in an environment that mimics the proprietary context. 16 Public release of code is encouraged for reproducibility but is not required under the NIH DMS Policy. 17

Updatable Code in a Companion Repository

At scale, there are two practical pathways to support updatable, executable code alongside frozen datasets. First, some generalist/archival repositories (and certain research data repositories) let authors co-locate a versioned code release with the cited data snapshot, preserving both with persistent identifiers (eg, DOIs) to ensure their long-term availability and integrity as an official record of research artifacts. 18 Second, data repositories can partner with modern code platforms (eg, via integrations) so that when authors create a formal code release, that exact version is archived and assigned its own DOI for citation and reproducibility. 19 In both scenarios, each new code release receives a distinct DOI (with links between versions), ensuring that readers can always retrieve the precise code for a specific analysis. Figure 2 illustrates how journals, data repositories, code repositories, and collaborative code platforms interact in the scientific process.

Figure 2.

Figure 2.

How journals, data repositories, code repositories, and collaborative code platforms interact to produce research objects and research records leading to dissemination and discovery.

Abbreviations: DOI, Digital Object Identifier; PID, Persistent Identifier.

An updatable companion repository lets code evolve through bug fixes, documentation, and new methods without changing what was cited in the publication. Authors can issue new releases with clear changelogs, while the manuscript continues to reference the original archived release/DOI used for its results. Framed this way, the repository becomes an open, version-controlled, community-maintained record. If code is submitted to a companion updatable repository, then future viewers may extend, update, or recompute the analyses, ensuring that the original work remains transparent and verifiable long after its initial appearance. 20

Benefits of Sharing Research Code in Companion Repositories

Submitting research code in a transparent companion repository with a persistent identifier such as a DOI, and citing or linking it within a journal article, enhances the study’s visibility and overall impact within the research community. 21 Code sharing also demonstrates transparency and a commitment to reproducibility, which can bolster the author’s reputation and that of their affiliated institution. 22 Practically, code sharing supports methodological rigor and error detection through verification by peers as well as serving as a foundation for new collaborations. 23

A citable companion code repository allows others to validate, reproduce, and build upon the work. These actions increase the credibility and trustworthiness of the published results and could lead to higher citation rates and greater recognition for the research, 24 although the topic has not been extensively studied. Furthermore, non-citation quantitative measures of impact, such as forks (new repositories created from existing ones) and downloads, reveal engagement and reuse of code. They can provide meaningful evidence of impact, although they are not represented by citations. 25 COARA (Coalition for Advancing Research Assessment) endorses several qualitative methods, such as peer review and expert opinion, for recognizing the impact of code that goes beyond traditional citation metrics. 26 In the same way that article- and dataset-level metrics have matured (eg, Altmetric attention scores for papers/software, 27 Make Data Count/DataCite usage, 28 and citation tracking), 29 code repositories are on a similar trajectory. As community norms around software citation, versioned DOIs for releases, and standardized usage signals continue to evolve and gain traction, companion code repositories will increasingly serve as recognized, citable scholarly outputs with impact that is measurable alongside traditional citations.

Potential Barriers

Direct costs are typically minimal for public repositories on platforms such as GitHub or GitLab, but indirect costs related to the time and effort burden of documentation, organizing code, environment capture, and maintenance can be substantial. Dedicated funding for these efforts may be needed to secure contributions and ensure sustainability. Researchers who share code may worry that competing groups may use their code without giving them adequate credit, especially if they have not yet published all intended results or completed larger projects that rely on that code. Clear license terms can help define how the code may be used.

The primary goal of most open research code repositories is to make code freely available under recognized open-source licenses for reuse, as well as to collaborate in research and software development under licenses like MIT (Massachusetts Institute of Technology), 30 GNU (GNU’s Not Unix), 31 or CC (Creative Commons). 32 Without an explicit open-source license, code is proprietary and not legally reusable. However, practical constraints can override or limit openness. Sharing code in a code repository is subject to privacy and confidentiality protection as well as (1) policies of the funding bodies and their institutions, (2) restrictions and policies set by applicable federal, Tribal, state, and local laws, and (3) existing or anticipated agreements. 17 In industry-sponsored studies, contracts often constrain code release (eg, intellectual property ownership, embargoes, or review clauses). When sharing is limited, journals can still encourage verification bundles so reviewers can evaluate methods without disclosing proprietary data. Finally, code from industry-sponsored studies is typically not shared, and research contracts often prohibit such sharing. 33

Conclusions

We expect two reinforcing trends in code sharing over the next few years. First, we anticipate increased encouragement and infrastructure for research code sharing across funders and journals. Many medical researchers—NIH-funded or not—are already archiving code snapshots alongside data deposits. Second, we anticipate that voluntary archiving of code in companion repositories by medical researchers will become more prevalent, which will facilitate greater transparency, reproducibility, and reuse of research software.

We commend NIH for its Gold Standard Science initiative and encouragement of data and code sharing. Evidence from multiple assessments shows persistent reproducibility challenges across parts of biomedicine, and surveys report that many researchers perceive a problem, although estimates vary by field and method.19-21 Sharing executable, environment-pinned code with a cited data snapshot makes work more transparent and testable, and thus more trustworthy and potentially more impactful. Over time, such contributions will shift the culture of medical science toward one that embodies the rigor envisioned in NIH’s Gold Standard plan.

Acknowledgments

The authors thank Annamarie Sucher-Jones for her expert editorial assistance.

Footnotes

Abbreviations: AI, artificial intelligence; CC, Creative Commons; CCR, Companion Code Repositories; COARA, Coalition for Advancing Research Assessment; DMS, data management and sharing; DOI, digital object identifier; FAIR, findable, accessible, interoperable, reusable; FAIR4RS, findable, accessible, interoperable, reusable for research software; GNU, GNU’s Not Unix; GSS, Gold Standard Science; MIT, Massachusetts Institute of Technology; NIH, National Institutes of Health; PID, Persistent Identifier; TRUST, transparency, responsibility, user focus, sustainability, technology.

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DCK is a consultant for Afon, Atropos Health, Embecta, Glooko, Glucotrack, Lifecare, Novo Nordisk, SynchNeuro, and Thirdwayv. JE receives funding the Helmsley Charitable Trust, and is a consultant for Sanofi, Glooko, and Dexcom. JKM is a member of advisory boards of Abbott Diabetes Care, Becton-Dickinson, Biomea Fusion, DexCom, Eli Lilly, Embecta, Medtronic, myLife, Novo Nordisk A/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem, and Viatris and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, DexCom, Eli Lilly, Medtrust, MSD, Novo Nordisk A/S, Roche Diabetes Care, Sanofi, Viatris, and Ypsomed. She is a shareholder of decide Clinical Software GmbH and elyte Diagnostics and serves as CMO of elyte Diagnostics. LH has received honoraria from Roche Diagnostics, Lifecare, Medtronic, Liom, Dexcom, OneTwenty, Perfood, Boydsense, PharmaSens, Unomedical, and Sinocare for lectures and participation in advisory boards. LH is a shareholder in Profil Institut für Stoffwechselforschung GmbH, diateam GmbH, and Science Consulting in Diabetes GmbH. DK’s institution has received research support from Abbott Diabetes Care. BKo reports receiving research support from DexCom, Inc and Tandem Diabetes Care handled by the University of Virginia and patent royalties from DexCom, Inc. handled by the University of Virginia’s Licensing and Ventures Group. BN has served as a consultant for BioSensics and Mölnlycke on studies unrelated to the scope of this manuscript. PP has consulted for Sanofi. DMM has consulted for Abbott, the Helmsley Charitable Trust, Lifescan, Sanofi, Medtronic, Provention Bio, Kriya, Biospex, and Bayer. GEU has received research support for Emory University from Bayer, Corcept, Abbott, Glucotrack, and Dexcom, and has participated in advisory boards for Dexcom, Corcept, Glucotrack, and Glycare. TYW is a consultant for Bayer, Boehringer-Ingelheim, Carl Zeiss, Genentech, Quaerite Biopharm Research Ltd, Roche, and Shanghai Henlius. He is an inventor, holds patents, and is a cofounder of start-up companies EyRiS and Visre, which have interests in, and develop digital solutions for eye diseases. AMA is an independent Board Advisor. No funding from any agency or Industry. MSDA is presently engaged in investigator-initiated research sponsored by Dexcom with discounted CGM devices. DTA has received speaker’s and/or consulting fees from Abbott, Ascensia, Lilly, Mannkind, Insulet, Novo, Sequel, and Xeris. He has received consulting/advisory fees from Lilly, Ascensia, and Mannkind. MEA has served on an advisory panel for Medtronic, Insulet, Abbott, VitalAire, Sanofi, and Dexcom, has received honoraria for speaking from Abbott, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and VitalAire; and has received research support from Medtronic and Sanofi. MAA Consultant for NNOXX, Inc. RB is a shareholder of Biomeris s.r.l. and Engenome s.r.l. EC is a Scientific Advisory Board Member/Consultant for Novo Nordisk, Eli Lilly, Arecor, Proventionbio, Portal Insulin, MannKind, Tandem, and Abbott. SLC has received research funding from i-SENS Inc., holds shares in Novo Nordisk A/S, and has received consultancy fees from Roche Diagnostics and Medicus Engineering. MAC is employed by Glooko and receives research support from Dexcom and Abbott Diabetes Care. KLC reports subscription fees and nonprofit contributions from multiple organizations. A full listing is available online at closeconcerns.com and diaTribe.org. JC is Medical Director of Teleophthalmology at Optain Health (formerly EyePACS). KD has received honoraria, travel, fees for speaking or advisory boards from Abbott Diabetes, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Menarini, Novo Nordisk, Roche, and Sanofi Diabetes. AFa is the principal investigator of research projects funded by Dexcom Inc. and co-investigator of research projects funded by Roche Diagnostics International Ltd. The funding was provided to his institution, and not directly to him personally. MALG has speaker fees: Medtronic, Sanofi, Roche, Abbott, and Novo Nordisk. TDH is a consultant for Acella and Amgen. PGJ reports receiving grants from the Leona M. and Harry B. Helmsley Charitable Trust, Breakthrough T1D, Dexcom, Eli Lilly, Oregon State University, and the Oregon Health & Science University Foundation; consultancy fees from Dexcom, Eli Lilly, Roche, 4YouAndMe, CDISC; US patents 62/352 939, 63/269 094, 62/944 287, 8 810 388, 9 480 418, 8 317 700, 61/570 382, 8 810 388, 7 976 466, and 6 558 321; and reports stock options from Pacific Diabetes Technologies, outside submitted work. BKu is head of the research institute of the diabetes academy Bad Mergentheim (FIDAM). BK has received speakers’ honoraria or consulting fees from Abbott, Bayer, Berlin Chemie, Dexcom, Embecta, Emperra, Lilly, Novo Nordisk, Roche, Sanofi, and Ypsomed. JLB is presently funded by: Helmsley Charitable Trust, Arizona Commerce Authority in Collaboration with Medtronic. AYL reports grants from Santen, personal fees from Genentech, personal fees from Johnson and Johnson, personal fees from Apellis, personal fees from Boehringer-Ingelheim, non-financial support from iCareWorld, grants from Topcon, grants from Carl Zeiss Meditec, personal fees from Gyroscope, non-financial support from Optomed, non-financial support from Heidelberg, non-financial support from Microsoft, grants from Regeneron, grants from Amazon, grants from Meta, outside the submitted work. DM has had research support from Breakthrough T1D, and the Helmsley Charitable Trust and his institution has had research support from Dexcom. DM has consulted for Abbott, Sanofi, Eli Lilly, Medtronic, Biospex, Kriya, and Enable Biosciences. NM has research support from Breakthrough T1D, and the Helmsley Charitable Trust. AAM is an employee of Alphabet and may own stock as part of the standard compensation package. SM has received speaker honoraria from Lilly UK, Menarini and Sanofi for educational presentations. SM is funded by a Wellcome Trust Career Development Award [223024/Z/21/Z] and is supported by the NIHR Imperial Biomedical Research Center. CR has received honoraria from AstraZeneca, Dexcom, Fresenius, and Vifor. DS is an advisor to Carta Healthcare. VNS’s institute has received research funding from Lilly, Enable Bioscience, Zucara Therapeutics, Cystic Fibrosis foundation, and Breakthrough T1D. VNS has received honoraria from Sanofi, Novo Nordisk, Lilly, Dexcom, Insulet, Tandem Diabetes Care, Medtronic, Sequel Med Tech, Abbott Diabetes, Roche, Biomea Fusion, and T1D Scout for advising, consulting, or speaking outside of this submitted work. MPS a cofounder and scientific advisor of Xthera, Exposomics, Filtricine, Fodsel, iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, and SensOmics. MPS is a scientific advisor of Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, Captify Inc, WndrHLTH, Yuvan Research, and Ovul. EKS is receiving research support (to Baltimore VA and University of Maryland) from Dexcom, Medtronic, Tandem Diabetes and Deka/Twist for the conduction of clinical trials. JS has served as an educator for Medtronic. She has received funding from Medtronic and Novo Nordisk; owns shares in Novo Nordisk and has been invited as part of the advisory board for Sanofi-Aventis; has received fees for speaking on behalf of Medtronic, Sanofi-Aventis, Rubin Medical, and Novo Nordisk. JV receives research support from Dexcom. AW conducts research with UnitedHealth Care. KW is a consultant for Astellas, a shareholder in WaShiLa Health, and has received research support from Astellas and Raxi. EW is an affiliate of the Diabetes Research Hub. RMW reports receiving research support as the site PI of sponsored clinical trials by Novo Nordisk, Lilly Diabetes and Sanofi, unrelated to this work. RMW reports serving as a consultant for Sanofi. MZ reports consulting for Dexcom, Inc. AC AD, AFle, AFS, AYD, BS, BWB, CC, CSL, DA, DL, EH, ER, FJD, GC, GD, HC, HR, IC, JCW, JF, JYC, KS, MAK, MMS, MV, NV, RA, RG, SAM, SJM, SNS, SY, TW, WAL, YMB, and YZ have nothing to disclose.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs: David C. Klonoff Inline graphic https://orcid.org/0000-0001-6394-6862

Juan Espinoza Inline graphic https://orcid.org/0000-0003-0513-588X

Julia K. Mader Inline graphic https://orcid.org/0000-0001-7854-4233

Lutz Heinemann Inline graphic https://orcid.org/0000-0003-2493-1304

Claudio Cobelli Inline graphic https://orcid.org/0000-0002-0169-6682

David Kerr Inline graphic https://orcid.org/0000-0003-1335-1857

Boris Kovatchev Inline graphic https://orcid.org/0000-0003-0495-3901

Bijan Najafi Inline graphic https://orcid.org/0000-0002-0320-8101

Priya Prahalad Inline graphic https://orcid.org/0000-0002-3894-4344

Yaguang Zheng Inline graphic https://orcid.org/0000-0002-8400-1398

Mandy M. Shao Inline graphic https://orcid.org/0009-0004-9550-9965

Agatha F. Scheideman Inline graphic https://orcid.org/0009-0008-4211-4934

Ashley Y. DuNova Inline graphic https://orcid.org/0000-0002-1478-7065

Michael Kohn Inline graphic https://orcid.org/0000-0001-5459-5044

Guillermo E. Umpierrez Inline graphic https://orcid.org/0000-0002-3252-5026

Tien Y. Wong Inline graphic https://orcid.org/0000-0002-8448-1264

Aiman Abdel Malek Inline graphic https://orcid.org/0009-0000-5549-1589

Michael S. D. Agus Inline graphic https://orcid.org/0000-0001-6454-6828

David T. Ahn Inline graphic https://orcid.org/0000-0002-8941-8459

Rawan AlSaad Inline graphic https://orcid.org/0000-0002-3235-0860

Mohammed E. Al-Sofiani Inline graphic https://orcid.org/0000-0003-4420-9378

David Armstrong Inline graphic https://orcid.org/0000-0003-1887-9175

Mark A. Arnold Inline graphic https://orcid.org/0000-0001-9375-1863

Yong Mong Bee Inline graphic https://orcid.org/0000-0002-5482-2646

B. Wayne Bequette Inline graphic https://orcid.org/0000-0002-6472-1902

Riccardo Bellazzi Inline graphic https://orcid.org/0000-0002-6974-9808

Eda Cengiz Inline graphic https://orcid.org/0000-0001-7992-9506

J. Geoffrey Chase Inline graphic https://orcid.org/0000-0001-9989-4849

Haipeng Chen Inline graphic https://orcid.org/0000-0003-0572-8888

Jake Y. Chen Inline graphic https://orcid.org/0000-0001-8829-7504

Simon L. Cichosz Inline graphic https://orcid.org/0000-0002-3484-7571

Ali Cinar Inline graphic https://orcid.org/0000-0002-1607-9943

Mark A. Clements Inline graphic https://orcid.org/0009-0002-4341-1697

Kelly L. Close Inline graphic https://orcid.org/0000-0001-7332-1380

Jorge Cuadros Inline graphic https://orcid.org/0000-0002-7804-5386

Ivan Contreras Inline graphic https://orcid.org/0000-0001-6896-818X

Gora Datta Inline graphic https://orcid.org/0000-0002-7783-296X

Ketan Dhatariya Inline graphic https://orcid.org/0000-0003-3619-9579

Francis J. Doyle III Inline graphic https://orcid.org/0000-0002-3293-9114

Andjela Drincic Inline graphic https://orcid.org/0000-0001-8365-7662

Andrea Facchinetti Inline graphic https://orcid.org/0000-0001-8041-2280

G. Alexander Fleming Inline graphic https://orcid.org/0000-0002-6549-0288

Joshua Foreman Inline graphic https://orcid.org/0000-0002-3685-4054

Monica A. L. Gabbay Inline graphic https://orcid.org/0000-0002-1300-9675

Ricardo Gutierrez-Osuna Inline graphic https://orcid.org/0000-0003-2817-2085

Elizabeth Healey Inline graphic https://orcid.org/0000-0002-7307-8429

Thanh D. Hoang Inline graphic https://orcid.org/0000-0001-7437-5604

Peter G. Jacobs Inline graphic https://orcid.org/0000-0001-9897-4783

Bernhard Kulzer Inline graphic https://orcid.org/0000-0001-9120-4479

Jeff La Belle Inline graphic https://orcid.org/0000-0003-4691-2702

Aaron Y. Lee Inline graphic https://orcid.org/0000-0002-7452-1648

Cecilia S. Lee Inline graphic https://orcid.org/0000-0003-1994-7213

Wei-An Lee Inline graphic https://orcid.org/0000-0002-2928-7338

Dorian Liepmann Inline graphic https://orcid.org/0000-0002-2591-4031

David Maahs Inline graphic https://orcid.org/0000-0002-4602-7909

Nestoras Mathioudakis Inline graphic https://orcid.org/0000-0002-0210-655X

Sultan A. Meo Inline graphic https://orcid.org/0000-0001-9820-1852

Ahmed A. Metwally Inline graphic https://orcid.org/0000-0002-0155-7412

Shivani Misra Inline graphic https://orcid.org/0000-0003-2886-0726

Helge Raeder Inline graphic https://orcid.org/0000-0001-9465-8580

Viswanathan Mohan Inline graphic https://orcid.org/0000-0001-5038-6210

Sun-Joon Moon Inline graphic https://orcid.org/0000-0002-6286-7254

Connie Rhee Inline graphic https://orcid.org/0000-0002-9703-6469

Eun-Jung Rhee Inline graphic https://orcid.org/0000-0002-6108-7758

David Scheinker Inline graphic https://orcid.org/0000-0001-5885-8024

Viral N. Shah Inline graphic https://orcid.org/0000-0002-3827-7107

Bin Sheng Inline graphic https://orcid.org/0000-0001-8678-2784

Michael P. Snyder Inline graphic https://orcid.org/0000-0003-0784-7987

Koji Sode Inline graphic https://orcid.org/0000-0002-9833-2091

Elias K. Spanakis Inline graphic https://orcid.org/0000-0002-9352-7172

Jannet Svensson Inline graphic https://orcid.org/0000-0002-9365-0728

Nitin Vaswani Inline graphic https://orcid.org/0009-0009-1586-4091

Maryam Vareth Inline graphic https://orcid.org/0000-0002-7827-2570

Josep Vehi Inline graphic https://orcid.org/0000-0001-6884-9789

Amisha Wallia Inline graphic https://orcid.org/0000-0002-3183-4062

Kayo Waki Inline graphic https://orcid.org/0000-0003-0046-2523

Tao Wang Inline graphic https://orcid.org/0000-0002-0865-0062

Eric Williams Jr Inline graphic https://orcid.org/0009-0002-8700-6722

Risa M. Wolf Inline graphic https://orcid.org/0000-0001-7674-520X

Jenise C. Wong Inline graphic https://orcid.org/0000-0003-0573-6650

Sewagegn Yeshiwas Inline graphic https://orcid.org/0000-0002-8153-7672

Mihail Zilbermint Inline graphic https://orcid.org/0000-0003-4047-7260

Shahid N. Shah Inline graphic https://orcid.org/0000-0001-8481-6493

References


Articles from Journal of Diabetes Science and Technology are provided here courtesy of Diabetes Technology Society

RESOURCES